Sjogren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment

被引：13

作者：

Komai, Koichiro ^{[2
]}

Shiozawa, Kazuko ^{[3
]}

Tanaka, Yasushi ^{[3
]}

Yoshihara, Ryosuke ^{[3
]}

Tanaka, Chihiro ^{[1
,3
]}

Sakai, Hideo ^{[3
]}

Yamane, Takashi ^{[3
]}

Murata, Miki ^{[3
]}

Tsumiyama, Ken ^{[2
]}

Hashiramoto, Akira ^{[1
,4
]}

Shiozawa, Shunichi ^{[1
,4
]}

机构：

[1] Kobe Univ, Grad Sch Med & Hlth Sci, Dept Med & Biophys, Div Rheumatol,Chuo Ku, Kobe, Hyogo 6500017, Japan

[2] Kobe Univ, Grad Sch Med & Hlth Sci, Dept Med & Biophys, Div Rheumatol,Suma Ku, Kobe, Hyogo 6540142, Japan

[3] Konan Kakogawa Hosp, Ctr Rheumat Dis, Kakogawa, Japan

[4] Kobe Univ Hosp, Ctr Rheumat Dis, Kobe, Hyogo, Japan

来源：

MODERN RHEUMATOLOGY | 2009年 / 19卷 / 04期

关键词：

Cevimeline; Dry mouth; Hyper gammaglobulinemia; Sjogren's syndrome; SALIVARY-GLANDS; XEROSTOMIA; PATHOGENESIS; ANTIBODIES; TRIAL; ALPHA; MICE;

D O I：

10.1007/s10165-009-0176-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by sicca symptoms, including dry eyes and dry mouth. Cevimeline is used for the treatment of dry mouth in patients with SS. Here we prospectively tested the clinical effectiveness of cevimeline at increasing saliva secretion in patients with SS, and the results were compared with the clinical parameters of the patients. Saliva secretion was increased > 160% in 17 of 30 (56.7%) patients (P < 0.005). When the clinical parameters were compared between the patients who responded to cevimeline treatment and those who did not respond to the treatment, the frequency of patients presenting with hypergammaglobulinemia was significantly higher in the nonresponder group (P < 0.05). It thus appears that cevimeline is effective in SS patients with milder disease activity.

引用

页码：416 / 419

页数：4

共 16 条

[11] The management of Sjogren's syndrome [J].

Mavragani, CP ;

Moutsopoulos, NM ;

Moutsopoulos, HM .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (05) :252-261

[12]

Miyawaki S, 2000, Ryumachi, V40, P48

[13]

Nakabayashi T, 1997, J IMMUNOL, V158, P5527

[14] ANALYSIS OF TRANSFORMING GROWTH-FACTOR-BETA AND OTHER CYTOKINES IN AUTOIMMUNE EXOCRINOPATHY (SJOGRENS-SYNDROME) [J].

OGAWA, N ;

DANG, H ;

LAZARIDIS, K ;

MCGUFF, HS ;

AUFDEMORTE, TB ;

TALAL, N .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1995, 15 (09) :759-767

[15] Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjogren's syndrome [J].

Shiozawa, S ;

Tanaka, Y ;

Shiozawa, K .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1998, 18 (04) :255-262

[16] Opening the flood gates -: Interferon-α treatment for Sjogren's syndrome [J].

Shiozawa, S ;

Cummins, JM ;

Fox, PC .

BIODRUGS, 2000, 13 (05) :305-311

← 1 2 →